| Methods | n = 45, 4 centres Allocation concealment: not described Baseline similarity: age, SAPS II, sepsis Blinding: caregivers Cointerventions: not described Withdrawals: treatment (1/23), control (2/22) Losses to follow‐up: none |
|
| Participants | Inclusions: AECC definition for ARDS Exclusion: Immunocompromised |
|
| Interventions | Continuous IV NAC, 190 mg/kg/day for 3 days (total dose 570 mg/kg), or placebo | |
| Outcomes | ICU mortality: RR 1.27 (95% CI 0.48 to 3.37), based on data from 42 patients Duration of ventilation: MD ‐1.2 days (95% CI ‐5.2 to 2.8), based on data from 42 patients Adverse events attributed to study medication: none |
|
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.